Last reviewed · How we verify
NCT03245437
Target Engagement and Response to Oxytocin
Completed
Phase 4
Last updated 21 March 2025
What this trial tests
Phase 4 trial testing Oxytocin nasal spray in Schizophrenia in 120 participants. Completed in 31 July 2024.
Timeline
4 January 2018
Primary endpoint
31 July 2024
31 July 2024
31 July 2024
Quick facts
| Lead sponsor | University of California, Los Angeles |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 4 January 2018 |
| Primary completion | 31 July 2024 |
| Estimated completion | 31 July 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Oxytocin nasal spray — full drug profile →
- Social Cognition Skills Training
- Health Management
- Placebo nasal spray — full drug profile →
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
University of California, Los Angeles
Who can join
Adults 18 to 65, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will measure whether the engagement of intranasal oxytocin with a brain target is related to effects on learning during a social cognition training program.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent Advances in Intranasal Administration for Brain-Targeting Delivery: A Comprehensive Review of Lipid-Based Nanoparticles and Stimuli-Responsive Gel Formulations.
Koo J, Lim C, Oh KT. · · 2024 · cited 57× · PMID 38414526 · DOI 10.2147/ijn.s439181 -
Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols.
Alabsi W, Eedara BB, Encinas-Basurto D, Polt R, et al · · 2022 · cited 44× · PMID 36145618 · DOI 10.3390/pharmaceutics14091870 -
Nose-to-Brain (N2B) Delivery: An Alternative Route for the Delivery of Biologics in the Management and Treatment of Central Nervous System Disorders.
Patharapankal EJ, Ajiboye AL, Mattern C, Trivedi V. · · 2023 · cited 37× · PMID 38258077 · DOI 10.3390/pharmaceutics16010066 -
New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery.
Li Y, Wu H, Jiang X, Dong Y, et al · · 2022 · cited 28× · PMID 35967290 · DOI 10.1016/j.apsb.2022.04.001 -
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.
Veselinović T, Neuner I. · · 2022 · cited 18× · PMID 35831706 · DOI 10.1007/s40263-022-00935-z
Verify or expand the search:
- PubMed search for NCT03245437
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oxytocin nasal spray
Trials testing the same drug.
- NCT07162584 — Oxytocin and Human Defensive Responses in a Dynamic Situation · NA · recruiting
- NCT06194851 — Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD · Phase 2 · recruiting
- NCT05934812 — Intranasal Oxytocin in Youth With Autism · Phase 2 · not yet recruiting
- NCT06881810 — Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment · Phase 2 · recruiting
- NCT06332066 — Oxytocin Administration to Therapists and Its Effects on Patient-perceived Attunement and Responsiveness · Phase 1 · unknown
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other University of California, Los Angeles trials
Trials by the same sponsor.
- NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
- NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
- NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
- NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
- NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03245437 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
- Last refreshed: 21 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03245437.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing